CLINICAL TRIALS PROFILE FOR LEXIVA

All Clinical Trials for Lexiva

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00085943 ↗	KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks	Completed	GlaxoSmithKline	Phase 3	2004-05-01	This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.
NCT00148785 ↗	A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir	Completed	Emory University	Phase 4	2005-07-01	When individuals who are infected with HIV are started on treatment with HIV medications, the effect of these drugs only lasts for a limited period of time, often because of development of drug resistance by the HIV virus. When this happens, such patients have to be switched to different combinations of HIV medications. However, since the availability of new HIV drugs that are active against resistant virus is limited, HIV care providers are resorting to curtail medications that contain three or more protease inhibitors (PIs). The reason for this is Norvir (ritonavir), a PI that has the ability to boost or increase the blood levels of other PIs in a way that can sometimes overcome the resistance of HIV virus. In addition, it may be more difficult for the virus to overcome two or more drugs with high blood levels, than it is to overcome just one. For these reasons, many clinicians are now using Norvir in combination with two other PIs, including Crixivan (indinavir) plus Lexiva (fosamprenavir), for treating patients who have been exposed to many other HIV medications. While this may be the case, researchers also know that when two or more PIs are combined, the effects each drug may have on the blood level of other drugs could be different. For example, researchers know from some recent studies that the combination of Norvir, Lexiva, and Kaletra, another PI, leads to an unacceptably low level of both Kaletra and Lexiva. Because researchers can not always assume that when multiple HIV medications are combined, the levels will remain high enough to be effective, the investigators think it will always be reasonable that, before any combination of drugs are used on HIV-infected patients, the effect a combination has on the levels of each of the drugs in the combination should be investigated. AIMS: The aim of this pilot study therefore is to examine the blood levels of Crixivan, Lexiva, and Norvir when these three drugs are used together as part of a combination treatment for HIV infection. METHODS: Fifteen (15) HIV-infected volunteers already being treated with a Crixivan and Norvir containing regimen will be recruited from the Grady Infectious Disease Clinic (IDP). Lexiva will be added to this regimen for 5 days, at the end of which participants will be admitted to the Grady General Clinical Research Center (GCRC) where blood samples will be collected at 9 different time points over 12 hours for measurement of blood drug levels. Pharmacokinetic Analysis: The blood concentrations of Crixivan, Lexiva, and Norvir will be measured by a special technique known as reverse-phase high-performance liquid chromatography with ultraviolet detection. Statistical Analysis: The blood level information will be summarized by a statistical method. The researchers will then compare the levels of Lexiva in this combination with historically published levels of Lexiva in a study of Lexiva plus Norvir; and that of Crixivan in a study of Crixivan plus Norvir. A difference of 30% or more in drug levels between this study and historical reports will be considered a significant difference.
NCT00363142 ↗	A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects	Completed	GlaxoSmithKline	Phase 3	2006-05-01	This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.
NCT00614991 ↗	An Interaction Study to Assess Drug Levels in Healthy Adult Subjects	Completed	GlaxoSmithKline	N/A	2008-01-01	To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir. COL111242 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and raltegravir (RTG) pharmacokinetics in 48 healthy, HIV-negative adults after administration of a 7-day regimen of RTG 400mg twice a day (BID) alone and after 14-day regimens of unboosted fosamprenavir (FPV) 1400mg twice daily (BID), FPV 700mg/Ritonavir (RTV) 100mg BID, or FPV 1400mg/ritonavir (RTV) 100mg once daily (QD) with and without concurrent RTG 400mg BID. Blood samples for drug concentration measurement will be collected over 12 hours at the end of each dosing period. Subjects will undergo a physical examination, complete blood count (CBC) with differential, HIV test, hepatitis B/C test, liver function test, renal function analysis, and lipid panel at screening, and all of these tests, except those for HIV and hepatitis B/C, will be repeated at follow-up post-study. Adverse events and adherence (by pill count and medication diary) will be assessed by the investigator/study personnel at the end of each dosing period
NCT00614991 ↗	An Interaction Study to Assess Drug Levels in Healthy Adult Subjects	Completed	Garden State Infectious Disease Associates, PA	N/A	2008-01-01	To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir. COL111242 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and raltegravir (RTG) pharmacokinetics in 48 healthy, HIV-negative adults after administration of a 7-day regimen of RTG 400mg twice a day (BID) alone and after 14-day regimens of unboosted fosamprenavir (FPV) 1400mg twice daily (BID), FPV 700mg/Ritonavir (RTV) 100mg BID, or FPV 1400mg/ritonavir (RTV) 100mg once daily (QD) with and without concurrent RTG 400mg BID. Blood samples for drug concentration measurement will be collected over 12 hours at the end of each dosing period. Subjects will undergo a physical examination, complete blood count (CBC) with differential, HIV test, hepatitis B/C test, liver function test, renal function analysis, and lipid panel at screening, and all of these tests, except those for HIV and hepatitis B/C, will be repeated at follow-up post-study. Adverse events and adherence (by pill count and medication diary) will be assessed by the investigator/study personnel at the end of each dosing period

Clinical Trial Conditions for Lexiva

Condition Name

Condition Name for Lexiva
Intervention	Trials
Healthy	3
HIV Infection	3
HIV Infections	3
Infection, Human Immunodeficiency Virus	2

Condition MeSH

Condition MeSH for Lexiva
Intervention	Trials
HIV Infections	8
Immunologic Deficiency Syndromes	4
Acquired Immunodeficiency Syndrome	4
Communicable Diseases	2

Clinical Trial Locations for Lexiva

Trials by Country

Trials by Country for Lexiva
Location	Trials
United States	56
Germany	4
Italy	3
Canada	3
Luxembourg	1

Trials by US State

Trials by US State for Lexiva
Location	Trials
California	5
New York	4
New Jersey	4
Maryland	3
Georgia	3

Clinical Trial Progress for Lexiva

Clinical Trial Phase

Clinical Trial Phase for Lexiva
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Lexiva
Clinical Trial Phase	Trials
Completed	11
Not yet recruiting	1

Clinical Trial Sponsors for Lexiva

Sponsor Name

Sponsor Name for Lexiva
Sponsor	Trials
GlaxoSmithKline	8
Garden State Infectious Disease Associates, PA	3
University of California, San Diego	1

Sponsor Type

Sponsor Type for Lexiva
Sponsor	Trials
Other	11
Industry	9
NIH	2

Lexiva Market Analysis and Financial Projection

Last updated: April 28, 2026

Lexiva (fosamprenavir): Clinical Trials Update, Market Analysis, and Projection

What is Lexiva and how is it used?

Lexiva is the brand name for fosamprenavir, an oral prodrug of amprenavir. It is used in HIV-1 treatment regimens in adults (and in approved pediatric populations, depending on country labeling). Fosamprenavir is typically administered with ritonavir boosting in current practice and historically in trial protocols, reflecting its pharmacokinetic profile.

---

What is the current clinical-trial status for Lexiva?

No active, high-enrollment, late-stage (Phase 3) Lexiva/fosamprenavir programs are evident in the modern trial landscape. The available trial record is dominated by:

• Older comparative and regimen-support studies (mostly pre-expansion of modern integrase-based regimens).
• Pharmacokinetic, formulation, and adherence-related studies that do not translate into major new efficacy signals.
• Regulatory and real-world data efforts tied to label maintenance rather than new mechanism-of-action development.

Because Lexiva is an established antiretroviral, the trial footprint is now largely maintenance-oriented, with limited global capital allocation to new Phase 3 outcomes.

Actionable read-through for R&D and BD

• The clinical bar for fosamprenavir is set by integrase inhibitor-based standards, so new pivotal trials face hard endpoints and recruitment constraints.
• Remaining opportunities typically sit in special populations, drug-drug interaction characterization, and formulation/PK work rather than brand-scale efficacy repositioning.

---

What is the market context for Lexiva?

Lexiva operates in the crowded HIV therapeutics market, where demand has shifted strongly toward integrase strand transfer inhibitor (INSTI) regimens and high-barrier combinations.

Market structure that pressures Lexiva

• INSTI-centered fixed-dose combinations have displaced many older protease inhibitor (PI) and non-INSTI regimens for first-line therapy in many markets.
• PI-based regimens persist for specific resistance profiles, tolerability needs, and clinical history, but uptake is slower and more concentrated.

Demand drivers that still support fosamprenavir

• Patients who need alternatives due to intolerance, resistance, or formulary constraints.
• Countries and payers where existing PI options remain clinically and economically embedded.
• Historic treatment continuity where patients have been stable for long periods on older regimens.

Demand constraints

• Competitive substitution by newer classes with simpler daily regimens and stronger resistance-to-failure profiles.
• Reduced clinician initiation in many settings as guidelines increasingly prioritize INSTI-based strategies.

---

How does Lexiva’s patent and exclusivity posture shape the forecast?

Lexiva’s long-established status implies that:

• Primary exclusivity has expired in major markets.
• Generic fosamprenavir exposure has likely constrained brand-level growth and pricing power for years.

This shifts the economics from “new patient capture” to:

• Retention and replacement-cycle behavior (where existing patients remain on therapy longer),
• Formulary substitution (where payers push generics),
• Local procurement and tender dynamics (which can cause short-term swings in unit demand).

---

What is the competitive set and why does it matter for projection?

Lexiva competes mainly with:

• Other protease inhibitor options (boosted PIs and once-daily variants where available).
• INSTI-based combinations that dominate guideline-directed first-line use.
• Other established non-INSTI strategies in regions with specific formulary constraints.

Projection consequence

• Competitive substitution is structurally unfavorable for brand-level revenue growth in the absence of new pivotal clinical differentiation.

---

Market Analysis and Projection Framework

Revenue model (high level)

For an established HIV therapy with generic competition, annual market outcomes typically track:

1. Patient numbers on therapy (retention effect).
2. Formulary pricing and tender cadence (brand premium collapses under generic dominance).
3. Switching rate away from older regimens toward INSTI-based options.

Scenario design (directional)

A credible projection for Lexiva over the medium term typically follows one of three trajectories:

Scenario	Patient retention	Pricing pressure	Annual demand direction
Base case	Moderate retention	Strong generic pressure	Flat to mild decline
Downside	Higher switching to INSTI	Aggressive tender-driven price compression	Mid single-digit decline
Upside	Slower switching in PI-restricted lines	Stable or favorable tender outcomes	Low growth or stabilization

Given class-level substitution dynamics and mature generic exposure, the base case is most consistent with a flat-to-mild decline market pattern.

---

Clinical and Commercial Implications

What does the clinical-trial environment imply for future label evolution?

With no visible pipeline of late-stage differentiation:

• Label expansions are more likely to be incremental (population refinements, dosing clarification, drug interaction updates).
• Commercial upside from new indications is unlikely.

Where can Lexiva still win in the market?

Lexiva is most likely to remain relevant through:

• Niche regimen use tied to resistance history or intolerance patterns.
• Formulary inertia where switches happen slowly due to stability on therapy.
• Payer-managed access where PI options remain stocked as alternatives.

---

Business Takeaways

Key Takeaways

• Lexiva is mature: clinical trial activity is mainly maintenance-oriented rather than new Phase 3 efficacy generation.
• Market structure is unfavorable for brand growth: INSTI-based regimens dominate treatment initiation, and generic fosamprenavir constrains pricing.
• Forecast expectation: the most supportable directional view is flat to mild decline with retention-driven stability rather than expansion.
• Commercial strategy for stakeholders should center on contracting/tender performance and retention in PI-appropriate patients, not new-patient growth from clinical differentiation.

---

FAQs

What is Lexiva’s active ingredient?

Lexiva’s active ingredient is fosamprenavir, a prodrug of amprenavir.

Is Lexiva still supported by new late-stage clinical evidence?

The visible modern trial landscape is dominated by non-pivotal studies; large Phase 3 programs that would drive major new efficacy repositioning are not apparent.

Why has demand for fosamprenavir softened?

HIV treatment standards have shifted toward INSTI-based regimens, which displace many older PI-anchored strategies.

How does generic competition affect Lexiva projections?

Generic fosamprenavir typically compresses brand pricing power, making revenue outcomes more dependent on patient retention and tender outcomes than on new uptake.

What is the most likely medium-term market trajectory?

A base-case pattern of flat to mild decline best fits a mature, generic-exposed antiretroviral in an INSTI-dominated market.

---

References

[1] US National Library of Medicine. ClinicalTrials.gov. Study records for fosamprenavir/LEXIVA (search results and record history). https://clinicaltrials.gov/
[2] FDA. Lexiva (fosamprenavir) prescribing information and related labeling. https://www.accessdata.fda.gov/
[3] European Medicines Agency (EMA). Lexiva EPAR and product information. https://www.ema.europa.eu/
[4] World Health Organization (WHO). HIV treatment guidelines (regimen recommendations and standard-of-care context). https://www.who.int/health-topics/hiv-aids